Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus

NCT01107132 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-04-20

No results posted yet for this study

Summary

In Type 2 Diabetes mellitus patients we will:

1. quantify vasculopathy and blood-retinal barrier (BRB) leakage
2. measure blood-brain barrier (BBB) permeability and neuroanatomical changes
3. correlate BRB pathology with BBB breakdown, inflammatory markers and neuropsychiatric sequela

Conditions

Sponsors & Collaborators

  • Soroka University Medical Center

    lead OTHER

Principal Investigators

  • Hadar Shalev, M.D · Soroka University Medical Center

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01107132 on ClinicalTrials.gov